TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Single Dose Study of ANX005 in Healthy Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male and females 18 years and older~* Females must be postmenopausal, surgically sterilized, or willing and able to use 2 methods of contraception throughout the study and for 1 month after the final study visit~* Willing and able to undergo vaccination if not vaccinated recently~Exclusion Criteria:~* History of any autoimmune disease, meningitis, septicemia or pneumonia~* History of hypercoagulable diseases, hyperviscosity, thrombosis, renal dysfunction or acute renal failure~* Known genetic deficiencies of the complement cascade system~* History of conditions whose symptoms and effects could alter protein catabolism or IgG utilization, e.g. protein-losing enteropathies or nephrotic syndrome~* Body weight less than 50 kg or greater than 100 kg~* Hypersensitivity or allergic reactions to any excipients in the ANX005 drug product~* (Cohorts 4b and 5b) Known selective IgA deficiency or presence of antibodies to IgA at screening~* (Cohorts 4b and 5b) Prior reaction or hypersensitivity to blood products, including IVIg or any of the excipients in IVIg.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- ANX005 Monotherapy (Type: EXPERIMENTAL): ANX005 intravenous infusion
- ANX005 and IVIg Combination Therapy (Type: EXPERIMENTAL): ANX005 intravenous infusion in combination with intravenous immunoglobulin (IVIg)
- Placebo (Type: PLACEBO_COMPARATOR): Placebo intravenous infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Metformin, Vitamin D, and Depression in Polycystic Ovary Syndrome (PCOS) Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Polycystic Ovary Syndrome diagnosis (Rotterdam Criteria)~* Vitamin D insufficiency (serum Vitamin D \<30 ng/mL)~* Insulin resistance~* Mild or greater severity of depression by Beck Depression Inventory-II~Exclusion Criteria:~* Current metformin use~* Vitamin D supplementation of \> 50,000 IU following confirmation of Vitamin D insufficiency~* Insulin-dependent diabetes mellitus~* Pregnancy or breastfeeding~* Untreated hypothyroidism~* Current active substance abuse~* Other major medical comorbidity: renal or hepatic dysfunction, severe pulmonary~* Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Metformin (Type: EXPERIMENTAL): Metformin 1000 mg PO bid
- Vitamin D (Cholecalciferol) (Type: EXPERIMENTAL): Cholecalciferol 5,000 IU PO daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Feasibility Study of a Fecal Incontinence Management System for Medical Use

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* The subject is at least 18 years of age~* The subject has fecal incontinence~Exclusion Criteria:~* The subject is pregnant and/or breastfeeding~* The subject has perianal fistulas and/or hemorrhoids~* It's estimated that the subject's perianal skin makes it inappropriate for subject to participate in the study (i.e. in case of damaged skin, very sweaty skin or very sinuous and folded skin)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fecal Incontinence management system (Type: EXPERIMENTAL): Fecal Incontinence Management System is based on the same principle as fecal pouches. A barrier around anus to ensure adhesion and prevent leakage.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Oral Therapies in Oncology: Cognitive Function and Compliance

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age over 18 years,~* Patients treated with a first prescription of exclusive oral therapy (chemotherapy and/or targeted therapy) as part of a cancer,~* Patients who begin treatment with ZYTIGA ® (abiraterone acetate) are incluables,~* Patients with asymptomatic brain metastases are incluables,~* Lack of personality disorders and psychiatric illness scalable,~* Knowledge of spoken and written French,~* Having signed the informed consent of study participation.~Exclusion Criteria:~* Pathology psychiatric~* Refusal to participate,~* Patient unable to respond to cognitive tests, - Documented use of drugs,~* Heavy drinking, - Cancer primitive central nervous system, - Participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Managing Pain in Patients With Plantar Fasciitis - A Blinded Randomized Controlled Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients (over 18 years old) with plantar fasciitis~* Adults who are competent and able to consent on their own behalf~* Patients who are seen at MGH Boston, MGH Waltham and Newton Wellesley Hospital~Exclusion Criteria:~* Patients who received an injection in the last 6 months in their plantar fascia~* Patients who will need to be treated surgically~* Patients who are non-English speaking

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Carbon fiber insole (Type: EXPERIMENTAL): assigned carbon fiber insole
- Polyurethane (Type: ACTIVE_COMPARATOR): Assigned polyurethane insole
- Polyethylene (Type: ACTIVE_COMPARATOR): assigned polyethylene insole

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness Study of the BOA(R)-Constricting IV Band

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Paramedics employed by the City of Houston or nurses employed by Memorial Hermann Hospital - Texas Medical Center~* Agree to participate through written consent process~Exclusion Criteria:~* City of Houston paramedics and Memorial Hermann Hospital - Texas Medical Center nurses who do not provide written informed consent to participate

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- BOA(R) (Type: EXPERIMENTAL): Nurse or paramedic uses the BOA(R)-Constricting IV Band to attempt placement of an upper extremity IV in an adult
- Standard care (Type: ACTIVE_COMPARATOR): Nurse or paramedic uses standard IV starting technique in the upper extremity of adults

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Prophylactic Use of Antibiotics for Through and Through Lacerations of the Lip

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* any individual who presents with a through-and-through laceration of the lip within twenty-four hours of injury~Exclusion Criteria:~* patients less than eighteen years of age~* pregnancy~* currently taking antibiotics~* animal or human bites~* wounds greater than 24 hours old~* diabetic patients~* immune compromised patients~* patients who require antibiotics for other sustained injuries~* patients with an allergy to penicillin or cephalosporin will be excluded if randomized to the cephalexin treatment group

- Gender: ALL
- Minimum Age: 18 Months
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- keflex (Type: EXPERIMENTAL): keflex 500mg twice a day for five days
- placebo (Type: PLACEBO_COMPARATOR): placebo 500mg twice a day for five days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study in the Treatment of Chronic Diabetic Foot Ulcers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Has signed a written informed consent prior to the first study intervention~* Is at least 18 and \<85 years of age~* Has one or more diabetic foot ulcers on the target limb, with only one marked for the study (target ulcer). It must have the following characteristics:Plantar; Grade 2 per Curative Health Services Classification; Non-infected; Neuropathic; Non-malignant; At least 1.0-25cm\^2 post-debridement; Present for at least 6 weeks~* Has Type I or II Diabetes Mellitus with an HBA1c between 6-10%~* Has a maximum fasting blood glucose level of 13.8 mmol/L~* An ankle-brachial systolic pressure index between 0.7 and 1.3~* If female and of childbearing potential has a negative serum pregnancy test and is neither breastfeeding or intending to become pregnant during the study~* Able and willing to attend the scheduled visits and comply with study procedures.~Exclusion Criteria:~* Known or suspected disease of the immune system~* Active or untreated malignancy or active, uncontrolled connective tissue disease~* Treatment with immunosuppressive or chemotherapeutic agents, radiotherapy or systemic corticosteroids less than 30 days before enrollment~* Presence of necrosis, purulence or sinus tracts that cannot be removed by debridement~* Has undergone revascularization procedure aimed at increasing blood flow in the treatment target limb \< 4 weeks prior to enrollment~* Active febrile illness~* AST, ALT, ALP \>3x the normal upper limit~* Serum Creatinine \>2x the normal upper limit~* Osteomyelitis~* Active Charcot~* Use of any topical treatments other than SOC (standard of care)at the time of enrollment~* Enrollment in any investigational clinical trial within 30 days of the screening visit~* Known or suspected hypersensitivity to any study product components~* Recent or current history of alcohol or drug abuse~* Any condition, which in the opinion of the Investigator, would interfere with the evaluation of the study product or poses a health risk to the subject~* All site personnel directly affiliated with this study and their immediate families

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 84 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Phase II, Randomized, Cross-Over, Vehicle-Controlled, Double-Blind, Multicenter Study of the Safety, Pharmacodynamics, and Preliminary Efficacy of GHRP-1/AG in Subjects With ESRD on Hemodialysis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects with ESRD who have been on HD for at least 3 months and have a urea reduction rate (URR) of at least 65%.~* Subjects who are 18 to 70 years of age.~* Subjects who have a body mass index (BMI) less than 30, albumin greater than 3.3 g/dL, and MIS of 5 to 10 (inclusive).~Exclusion Criteria:~* Subjects who have diabetes and are currently taking insulin.~* Subjects who have a history of or current significant central nervous system (CNS) disorders.~* Subjects who have active infection at baseline.~* Subjects who have active or unstable cardiac or arterial disease.~* Subjects who have uncontrolled tertiary hyperparathyroid condition.~* Subjects who have anemia.~* Subjects who have a history of hepatitis or current liver disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Total Therapy Study XIV for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of non-B-cell leukemia by immunophenotyping (e.g. T-cell, B-cell precursor, or acute undifferentiated leukemia)~* Ages less than or equal to 18 years of age~* One week or less of prior therapy, limited to glucocorticoids, vinca alkaloids, emergency radiation therapy to the mediastinum and one dose of intrathecal chemotherapy Exclusion Criteria~* Participants greater than 18 years of age

- Gender: ALL
- Minimum Age: None
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Phase II Study of Avastin + Erbitux + Irinotecan as 2nd Line Treatment of Colorectal Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed locally advanced or metastatic colorectal cancer.~* Measurable or evaluable disease according to the Response Evaluation Criteria in Solid Tumors (RECIST)~* ECOG performance status ≤ 2~* Age 18 - 72 years~* Patients with de novo refractory disease (progression of disease as best response at 1st line therapy with FOLFOX/Avastin)~* Adequate liver (Bilirubin ≤ 1.5 UNL, SGOT/SGPT ≤ 4 UNL, ALP ≤ 2.5 UNL),renal (Creatinine ≤ 1.5 UNL) and bone marrow (ANC ≥ 1,500/mm3, PLT ≥100,000/mm3) function~* Patients must be able to understand the nature of this study~* Written informed consent~Exclusion Criteria:~* History of serious cardiac disease (unstable angina, congestive heart failure, uncontrolled cardiac arrhythmias).~* History of myocardial infarction or stroke within 6 months.~* Clinically significant peripheral vascular disease.~* History of abdominal fistula, gastrointestinal perforation or intraabdominal abscess within 28 days prior to Day 0.~* Presence of central nervous system or brain mets.~* Evidence of bleeding diathesis or coagulopathy.~* Patients with known hypersensitive reaction to cetuximab~* Blood pressure \> 150/100 mmHg.~* Pregnant or lactating woman.~* Life expectancy \< 3 months.~* Previous radiotherapy within the last 4 weeks or \> 25% of bone marrow.~* Metastatic infiltration of the liver \>50%.~* Patients with chronic diarrhea (at least for 3 months) or partial bowel obstruction or total colectomy.~* Active infection requiring antibiotics on Day 1.~* Second primary malignancy, except for non-melanoma skin cancer and in situ cervical cancer.~* Psychiatric illness or social situation that would preclude study compliance.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 72 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Irinotecan+Avastin+Erbitux

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Biomarkers, Neurodevelopment and Preterm Infants

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* \<32 weeks gestation~* Born at Weiler Division of Montefiore~Exclusion Criteria:~* Intraventricular hemorrhage~* Chromosomal abnormalities~* Congenital viral conditions

- Gender: ALL
- Minimum Age: 1 Day
- Maximum Age: 2 Days
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: None): Preterm infants \<32 weeks gestational age

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Vitamin D to Prevent Severe Asthma Exacerbations (Vit-D-Kids Asthma)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 6 to 16 years old~* Physician-diagnosed asthma for at least one year~* At least one severe asthma exacerbation in the previous year~* Use of asthma medications (daily controller medication \[ICS or leukotriene inhibitor\] or inhaled β2-agonist \[at least three days per week\]) for at least six months in the previous year~* Vitamin D insufficiency (i.e., serum vitamin D (25(OH)D level \<30 ng/ml (75 nmol/L))~* FEV1 ≥70 % of predicted~* Positive bronchodilator response (i.e., increase in FEV1 ≥8% from baseline after inhaled short acting beta agonist or increased airway responsiveness to methacholine (PC20 ≤8 mg/ml if not on ICS or PC20 ≤16 mg/ml if on ICS)~* Study protocol (i.e., age-appropriate dose of Fluticasone and no other asthma controller medications) approved by the child's regular doctor~* Parental consent and child's assent to participate in the study.~Additional inclusion criteria applied after the run-in period, to be eligible for randomization:~* Adherence with ICS and study medication (≥75% use \[at least 21 of 28 days\]) during the run-in period~* Willingness to be randomized and complete study~Exclusion Criteria:~* Serum calcium \>10.8 mg/dl~* Serum 25(OH) D \<14 ng/ml (35 nmol/L)~* Chronic respiratory disorder other than asthma~* Severe asthma (intubation for asthma at any time OR ≥3 hospitalizations for asthma in previous year OR ≥6 severe asthma exacerbations in previous year)~* Hepatic/renal disease, rickets, malabsorption, or other diseases that would affect vitamin D metabolism~* Current smoking, or former smoking if ≥5 pack-years~* Immune deficiency, cleft palate or Down's syndrome~* Treatment with anticonvulsants or ≥1,000 IU/day of vitamin D2 or D3~* Chronic oral corticosteroid therapy~* Inability to perform acceptable spirometry~* Use of investigational therapies or participation in trials 30 days before or during the study~* Participant is currently breast feeding an infant~* Pregnancy~* Weight less than 10 kg~* Plans to move out of the study site area in the next year~Additional exclusion criteria applied after the run-in period:~* Any severe asthma exacerbation during the run-in period~* Need for asthma medications other than ICS and p.r.n. rescue inhalers during the run-in period

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- vitamin D3 (Type: EXPERIMENTAL): Cholecalciferol (Vitamin D3) 4000 IU oral gel cap daily
- placebo (Type: PLACEBO_COMPARATOR): placebo formulations will be in gel cap form and identical to the active drug

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Gender and Pubertal Status on Human Plasmacytoid Dendritic Cells. PLASMACYTOKID

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Pediatric patients (0-18 years old):~   * Group 1 : Age\<8 years old~  * Group 2 : Age\>12 years old~2. Body weight \>10kgs~3. Pubescent (group 2) or non-pubescent (group 1)~4. Written consent of parents~Exclusion Criteria:~1. Active infectious disease~2. Known perturbations of immune and/or inflammatory systems~3. Oral or subcutaneous contraception in pubescent girls

- Gender: ALL
- Minimum Age: None
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Group 1: non-pubescent children (Type: EXPERIMENTAL): 70 non-pubescent children (25 healthy boys, 25 healthy girls, 10 boys with Klinefelter syndrome and 10 girls with Turner syndrome) Two 7 ml tubes of blood will be taken to perform the functional assays as well as the quantification of Blood Plasmacytoid dendritic cells (pDCs) absolute number in this 70 non-pubescent children.
- Group 2: pubescent healthy children (Type: EXPERIMENTAL): 50 pubescent healthy children (25 boys and 25 girls) Two 7 ml tubes of blood will be taken to perform the functional assays as well as the quantification of Blood Plasmacytoid dendritic cells (pDCs) absolute number in this 50 pubescent healthy children.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues